Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

388
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
388
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.5K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.0K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.0K
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

20
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
20
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

205
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
205
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

257
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
257

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hospice Enrollments From The Emergency Department Feature Short Admissions And High-Acuity Hospice Care.

Health affairs (Project Hope)·2026
Same author

Public Health.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Automate Creating, Customizing, and Optimizing Comorbidity Indices Using a Data-Driven AI/ML Approach.

Studies in health technology and informatics·2025
Same author

A Primer for Big Data Research: A Protocol Reflection.

The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses·2025
Same author

Usability Testing of the PACE-App to Support Family Caregivers in Managing Pain for People With Dementia.

The Gerontologist·2024
Same author

How Do Nurses Assess Cognition in Adults With Neurological Conditions? A Scoping Review.

Rehabilitation nursing : the official journal of the Association of Rehabilitation Nurses·2024

Related Experiment Video

Updated: Feb 17, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.7K

Using simulation and optimization approach to improve outcome through warfarin precision treatment.

Chih-Lin Chi1, Lu He, Kourosh Ravvaz

  • 1School of Nursing & Institute for Health Informatics University of Minnesota, Minneapolis, MN, USA, cchi@umn.edu.

Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing
|December 9, 2017
PubMed
Summary

This study developed precision warfarin treatment plans using patient simulations. Sub-population optimization offers a cost-effective approach to minimize adverse risks for large patient groups.

More Related Videos

Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models
06:16

Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models

Published on: April 19, 2024

1.9K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K

Related Experiment Videos

Last Updated: Feb 17, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.7K
Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models
06:16

Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models

Published on: April 19, 2024

1.9K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K

Area of Science:

  • Pharmacogenomics
  • Computational Biology
  • Clinical Decision Support

Background:

  • Warfarin dosing requires careful management due to its narrow therapeutic index and genetic variability.
  • Current warfarin treatment protocols often lack personalization, leading to suboptimal outcomes and increased adverse events.

Purpose of the Study:

  • To develop and evaluate a simulation and optimization approach for precision warfarin treatment planning.
  • To create decision support guidance for implementing precision warfarin therapy.

Main Methods:

  • Utilized a data-driven and domain-knowledge based Bayesian Network Model to generate approximately 1,500,000 clinical avatars (simulated patients).
  • Simulated 30-day patient responses to five different clinical and genetic warfarin treatment plans.
  • Performed individual and sub-population based optimization using the property of minimal entropy to minimize adverse risks.

Main Results:

  • Sub-population optimization demonstrated a more cost-effective and realistic implementation strategy compared to individual optimization.
  • The approach successfully minimized overall adverse risks for large patient sub-populations.
  • Decision support rules were developed based on sub-population optimized outcomes.

Conclusions:

  • Precision warfarin treatment plans guided by sub-population optimization can improve patient outcomes.
  • The developed simulation and optimization framework provides a viable tool for clinical decision support in warfarin therapy.
  • Balancing transparency and ease of implementation is crucial for the practical adoption of precision medicine approaches.